These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2575985)

  • 1. Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring.
    Withagen AJ; Corbeij HM; Huige MC; Kragten JA; Vermeulen A
    Drugs; 1989; 38 Suppl 2():67-9. PubMed ID: 2575985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance.
    Rydén L
    J Intern Med; 1992 Jan; 231(1):7-11. PubMed ID: 1346268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative multicentre study of the tolerability and efficacy of epanolol versus metoprolol in patients with stable angina pectoris.
    Clark-Turner N
    Drugs; 1989; 38 Suppl 2():55-60. PubMed ID: 2575982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left ventricular function during treatment with either metoprolol or epanolol.
    Evans T
    Drugs; 1989; 38 Suppl 2():70. PubMed ID: 2575986
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale and statistical methodology for the VISA studies.
    Ratcliffe MJ; Godley MJ
    Drugs; 1989; 38 Suppl 2():50-4. PubMed ID: 2575981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a single oral administration of Epanolol on exercise tolerance in patients with stable effort angina pectoris.
    Vandenbosch H; Piessens J; De Geest H
    Acta Cardiol; 1991; 46(1):11-25. PubMed ID: 1674394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of epanolol versus metoprolol in angina pectoris. Results from the Swedish Multicenter Study of Exercise Tolerance. The Swedish Multicenter Study Group.
    Rydén L
    Drugs; 1989; 38 Suppl 2():66. PubMed ID: 2575984
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative multicentre study of the tolerability and efficacy of epanolol versus nifedipine in patients with stable angina pectoris.
    Readman AS
    Drugs; 1989; 38 Suppl 2():61-5. PubMed ID: 2575983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity in stable angina pectoris. The Visacor Study Group.
    Boberg J; Larsen FF; Pehrsson SK
    Clin Cardiol; 1992 Aug; 15(8):591-5. PubMed ID: 1354086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epanolol. A new once-daily antianginal agent: dose finding and long term efficacy.
    Akhras F; Jackson G
    Drugs; 1989; 38 Suppl 2():28-34. PubMed ID: 2575977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of epanolol in elderly patients with stable angina pectoris.
    Marlier R; McAinsh J; Cockshott ID
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):142-4. PubMed ID: 1970734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol versus metoprolol in the acute phase of myocardial infarction:
    Bonnemeier H; Ortak J; Tölg R; Witt M; Schmidt J; Wiegand UK; Bode F; Schunkert H; Richardt G
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S222-6. PubMed ID: 15683501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of clinical trial experience with epanolol.
    Blake P
    Drugs; 1989; 38 Suppl 2():81-5. PubMed ID: 2575988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease.
    Wright RA; Perrie AM; Stenhouse F; Alberti KG; Riemersma RA; MacGregor IR; Boon NA
    Eur J Clin Pharmacol; 1994; 46(3):279-82. PubMed ID: 7915237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variation of heart rate variability and the rate of autonomic change in the morning hours in healthy subjects and angina patients.
    Wennerblom B; Lurje L; Karlsson T; Tygesen H; Vahisalo R; Hjalmarson A
    Int J Cardiol; 2001 Jun; 79(1):61-9. PubMed ID: 11399342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epanolol as a model for assessing patient preference in anti-anginal drug therapy.
    Blake P; Lewis JA
    J Clin Pharmacol; 1992 Jan; 32(1):85-90. PubMed ID: 1346791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction.
    Van Den Heuvel AF; van der Ent M; van Veldhuisen DJ; Kruijssen DA; Bartels GL; Remme WJ
    J Cardiovasc Pharmacol; 1998 Apr; 31(4):506-12. PubMed ID: 9554797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of heart rate variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina pectoris.
    Brouwer J; Viersma JW; van Veldhuisen DJ; Man in 't Veld AJ; Sijbring P; Haaksma J; Dijk WA; Lie KI
    Am J Cardiol; 1995 Oct; 76(11):759-63. PubMed ID: 7572650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of possible pharmacokinetic and pharmacodynamic interactions between epanolol and digoxin.
    Lefebvre RA; Bogaert MG; Duprez D
    Eur J Clin Pharmacol; 1990; 38(5):505-7. PubMed ID: 1974206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of beta-adrenoceptor antagonists with and without partial agonist activity on exercise tolerance and muscle lactate production.
    Lees KR; Curzio J; Farish E; Borland WW; Rubin PC
    Eur J Clin Pharmacol; 1987; 33(4):415-7. PubMed ID: 2894994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.